An HLA-DR genetic test identifies variants in immune-system genes that encode HLA class II proteins, especially HLA-DRB1 and, when present, DRB3, DRB4, or DRB5. The test is central to blood stem cell donor matching and can also contribute to organ transplant assessment, autoimmune disease research, and selected diagnostic evaluations. In transplantation, a result is interpreted by comparing the recipient’s alleles with a potential donor’s alleles and by checking whether the recipient has antibodies against mismatched HLA targets. In autoimmune medicine, certain HLA-DR alleles raise or lower statistical susceptibility, but they do not prove that a person has rheumatoid arthritis, type 1 diabetes, multiple sclerosis, or another disorder. Testing usually uses blood or a cheek swab, requires no fasting, and remains valid for life. The report’s resolution, allele pairs, linked HLA-DQ haplotypes, antibody findings, transplant type, and treatment plan all affect its meaning.
- HLA-DR typing identifies inherited alleles; transplant compatibility requires donor-recipient comparison rather than a normal or abnormal range.
- HLA-DRB1 is one of the core high-resolution loci used for unrelated blood stem cell donor matching.
- A mismatch may increase immune risk, but modern graft sources and graft-versus-host disease prevention can make selected mismatched transplants possible.
- Autoimmune-associated HLA-DR alleles show susceptibility only and cannot diagnose disease without clinical and laboratory evidence.
- Blood and cheek-swab samples need no fasting, medication changes, or special timing.
Table of Contents
- What the HLA-DR test measures
- HLA-DR in transplant matching
- Sample collection, resolution, and reporting
- How to interpret a donor-recipient result
- HLA-DR and autoimmune disease risk
- HLA antibodies, DSA, and crossmatch
- Limitations and common misunderstandings
- Next steps after testing
What the HLA-DR test measures
HLA means human leukocyte antigen. HLA proteins help immune cells distinguish the body’s own tissues from foreign material. HLA-DR belongs to class II, a group found mainly on antigen-presenting cells such as dendritic cells, B cells, and macrophages. These proteins display peptide fragments to CD4 T cells and shape immune responses.
The main HLA-DR protein contains an alpha chain and a beta chain. The alpha chain varies relatively little. Most clinically important diversity comes from HLA-DRB1, which is present in everyone. Depending on the DRB1 haplotype, a person may also carry HLA-DRB3, HLA-DRB4, or HLA-DRB5. These secondary DR genes can matter in detailed transplant matching and antibody analysis.
Each person normally inherits one HLA haplotype from each biological parent. A haplotype is a linked set of HLA alleles, often including DRB1, DQA1, and DQB1. A report might show DRB103:01 and DRB115:01, with linked DQ alleles. The asterisk separates the gene name from the allele designation. More digits indicate greater typing resolution.
There is no universally “good,” “bad,” high, or low HLA-DR value. The result is a genotype. Its meaning comes from context:
- In blood stem cell transplantation, the recipient and donor are compared allele by allele.
- In organ transplantation, matching, antibody targets, allocation rules, and organ-specific evidence are considered together.
- In autoimmune disease, selected alleles alter group-level susceptibility.
- In research, HLA-DR can help define immune subgroups or peptide responses.
HLA-DR typing differs from an HLA antibody test. Typing shows which inherited HLA proteins a person can make. Antibody testing shows whether the immune system has developed antibodies against HLA proteins that the person does not carry.
HLA-DR in transplant matching
HLA-DRB1 is a core locus in allogeneic hematopoietic cell transplantation, which includes bone marrow, peripheral blood stem cell, and cord blood transplantation. The transplanted donor immune system can recognize the recipient as foreign, while the recipient may reject donor cells. Close HLA matching reduces these immune differences.
For an unrelated adult donor, transplant programs commonly assess high-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1. Matching both inherited alleles at all four loci is called an 8/8 match. Some programs also refer to a 10/10 match when DQB1 is included, and they examine DPB1 and low-expression loci as additional selection factors.
A matched sibling has a one-in-four chance of inheriting the same two parental HLA haplotypes as the patient, although real family structure and testing determine the actual result. Half-matched, or haploidentical, relatives share one haplotype. Modern post-transplant cyclophosphamide and other prophylaxis approaches have expanded successful use of haploidentical and mismatched unrelated donors.
HLA-DRB1 matching remains important, but the best donor is not selected from HLA alone. Teams also consider:
- donor age and medical fitness;
- how quickly the donor can proceed;
- graft source and cell dose;
- recipient antibodies against donor HLA;
- disease urgency and status;
- cytomegalovirus status in selected settings;
- donor sex and pregnancy history;
- ABO compatibility;
- the planned graft-versus-host disease prevention regimen.
A lengthy search for a perfect match can be harmful when disease is advancing. Current donor-selection practice may favor moving promptly to a suitable alternative donor when an 8/8 unrelated donor is unlikely to be found. The exact balance depends on transplant center expertise and the patient’s disease.
In solid-organ transplantation, HLA-DR mismatching can influence rejection and long-term graft outcomes, especially in kidney transplantation. However, organs cannot always wait for an ideal match. Blood type, organ size, urgency, waiting time, donor quality, ischemia time, antibodies, and allocation policy also shape acceptance.
Sample collection, resolution, and reporting
HLA-DR typing usually uses a blood sample or cheek swab. Saliva may also be accepted. No fasting is needed. Medicines, diet, recent infection, pregnancy, and time of day do not change inherited alleles. A cheek sample should be collected according to instructions to obtain enough cells and reduce contamination.
Testing methods include polymerase chain reaction with sequence-specific primers or probes, Sanger sequencing, next-generation sequencing, and long-read sequencing. The method and laboratory workflow determine the resolution and whether ambiguous allele combinations remain.
| Report level | Example | Typical use |
|---|---|---|
| Antigen or low resolution | DR4, DR15, or DRB1*04 | Initial screening, older records, selected organ allocation contexts |
| Allele-level high resolution | DRB1*04:01 | Adult unrelated donor matching and detailed clinical interpretation |
| Extended typing | DRB1 plus DRB3/4/5 and linked DQ loci | Complex antibody or transplant risk assessment |
An initial registry cheek swab may provide enough information to identify possible donors, but confirmatory typing is performed before donation. Transplant laboratories use identity safeguards because a sample mix-up could have serious consequences. Donor and recipient typing may be repeated from separate samples.
Reports may contain two DRB1 alleles, secondary DRB genes, typing resolution, ambiguity codes, and a match summary. “Homozygous” means the assay found the same allele at both copies or could not distinguish two identical allele groups. It does not mean the person has only one HLA-DR protein overall.
When autoimmune risk is the question, the report may list an associated haplotype rather than a match score. A broad consumer report should be confirmed in a clinical laboratory before it affects diagnosis or treatment.
How to interpret a donor-recipient result
A transplant match report compares the alleles at specified loci. For HLA-DRB1, a full allele match means the donor and recipient have the same two tested DRB1 alleles at the required resolution. A mismatch means at least one donor allele differs.
Mismatch direction matters. In the graft-versus-host direction, donor immune cells can recognize a recipient HLA difference. In the host-versus-graft direction, the recipient can recognize donor cells. When a recipient is homozygous at a locus and a donor carries one shared and one different allele, the mismatch may be directional rather than bidirectional.
The biological effect of a mismatch is not identical for every allele pair. Amino acid differences change which peptides an HLA protein binds and which surfaces are visible to immune receptors. Molecular matching tools examine amino acid positions or eplets, small structural patches that antibodies may recognize. These tools can refine risk, but thresholds are not universal and do not replace established transplant protocols.
| Result phrase | Plain-language meaning | Usual response |
|---|---|---|
| 8/8 matched unrelated donor | Both alleles match at HLA-A, -B, -C, and -DRB1 | Consider other donor and graft factors before final selection |
| 7/8 mismatch | One allele differs across the four core loci | Assess locus, direction, antibodies, urgency, and prophylaxis strategy |
| Haploidentical donor | One parental HLA haplotype is shared | Use a center-specific haploidentical transplant approach |
| DRB1 matched, DRB3/4/5 mismatched | Main DRB1 alleles match but a secondary DR locus differs | Consider with other low-expression-locus and clinical factors |
| Donor-specific antibody present | Recipient antibody targets a donor HLA antigen or allele | Avoid that donor when feasible or use a specialist management plan |
A match percentage from a general DNA service is not a transplant match. Clinical matching requires validated high-resolution HLA data, correct locus coverage, and specialist interpretation.
The HLA-C result and HLA-DP result may also affect donor selection, but each locus is weighted according to transplant type and prophylaxis strategy.
HLA-DR and autoimmune disease risk
HLA-DR alleles influence how self and environmental peptides are presented to T cells. Strong associations exist with several autoimmune diseases, but the alleles are neither necessary nor sufficient in every patient.
Examples include:
- selected HLA-DRB1*04 and *01 alleles containing the shared epitope in seropositive rheumatoid arthritis;
- DRB103:01 and DRB104-linked haplotypes in type 1 diabetes;
- DRB1*15:01 in multiple sclerosis;
- DRB1*03:01 in several antibody-mediated autoimmune conditions;
- DRB1*04:01 in selected autoimmune liver and endocrine disorders, depending on population;
- DRB115:01-DQB106:02 in narcolepsy-related immune genetics, with DQB1 carrying the strongest classic association.
A risk allele can be common in healthy people. The same allele can be associated with more than one condition, and linked genes may contribute to the observed effect. Ancestry changes allele frequency and the strength of association. Therefore, HLA-DR testing usually does not belong in a general autoimmune screen.
For rheumatoid arthritis, symptoms, joint examination, inflammatory markers, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, and imaging are more clinically useful. For type 1 diabetes, islet autoantibodies and glucose measures matter more. For multiple sclerosis, neurologic assessment, MRI, and cerebrospinal fluid findings guide diagnosis.
HLA results may support a specialist’s differential diagnosis in selected situations or aid research classification. They do not tell whether inflammation is active, how severe disease will become, or which medication will work. The HLA-DRB1 shared epitope test is a more focused example of allele-level risk interpretation.
HLA antibodies, DSA, and crossmatch
Transplant compatibility requires both typing and antibody testing. A recipient can develop anti-HLA antibodies after pregnancy, blood transfusion, a prior transplant, or sometimes other immune exposure. When an antibody specifically recognizes an HLA allele or antigen present in a proposed donor, it is called a donor-specific antibody, or DSA.
HLA class II antibodies often target DR or DQ. A recipient may be perfectly healthy yet have sensitization that limits compatible donors. Conversely, an HLA mismatch is not automatically dangerous if the recipient has no antibody against it and the transplant strategy can manage T-cell alloreactivity.
Laboratories commonly use single-antigen bead assays to identify antibody specificity. Fluorescence strength is reported as mean fluorescence intensity, but MFI is semiquantitative. It varies with assay conditions, antigen density, interference, dilution, and laboratory thresholds. A number should not be interpreted without the pattern and clinical context.
A physical or virtual crossmatch asks whether the recipient is likely to react against the donor. A physical crossmatch mixes recipient serum with donor lymphocytes. A virtual crossmatch compares known antibody specificities with the donor’s HLA type. A positive result can signal high rejection risk, though the significance depends on test type and strength.
The PRA or calculated PRA result summarizes how broadly sensitized a candidate is. It does not replace the donor-specific assessment.
Limitations and common misunderstandings
HLA-DR testing is technically complex and context-dependent. Important limitations include incomplete locus coverage, low-resolution typing, unresolved phase, rare alleles, and differences among laboratories. A report produced for autoimmune research may not meet transplant requirements.
Common misunderstandings include:
- treating an allele as abnormal when it is a normal inherited variant;
- assuming siblings are automatically matches;
- thinking blood type predicts HLA compatibility;
- equating an 8/8 match with zero transplant risk;
- assuming any mismatch makes transplantation impossible;
- confusing HLA genotype with anti-HLA antibodies;
- diagnosing an autoimmune disease from an associated allele;
- relying on a consumer genotype for donor selection;
- comparing match scores that use different loci or resolution.
Even a fully HLA-matched transplant can cause graft-versus-host disease, rejection, infection, relapse, or other complications because minor histocompatibility antigens, immune history, disease status, conditioning, graft source, and medications also matter. A mismatched transplant can succeed when the donor, graft, and prophylaxis strategy are chosen carefully.
Autoimmune associations also do not provide individual certainty. Many people with risk alleles never become ill, and many patients lack the most familiar allele. HLA should not be used to reassure away symptoms or to justify treatment without a diagnosis.
Next steps after testing
For transplant evaluation, review the result with the transplant physician and histocompatibility laboratory. Confirm which loci were typed, whether results are high resolution, whether the sample was confirmatory, and whether donor-specific antibodies are present. Donor selection should proceed promptly enough for the underlying disease.
For an autoimmune-risk result, identify the exact clinical question. A person with symptoms needs disease-specific testing rather than broader HLA interpretation. A healthy carrier usually does not need serial HLA tests because the genotype does not change.
Family members should be tested directly when they are potential donors. Do not infer compatibility from appearance, blood type, ancestry, or another relative’s result. Registry searches can identify unrelated donors with similar HLA haplotypes, although access to well-matched donors varies across ancestral backgrounds.
Ask the clinician to explain the result in plain terms: which alleles match, which differ, whether a mismatch is clinically important, whether an antibody targets it, what alternatives exist, and whether waiting for another donor would improve or worsen overall risk.
Questions that clarify a transplant report
A match label is meaningful only when the loci and resolution are named. Ask whether “8/8” means allele-level HLA-A, -B, -C, and -DRB1 matching and whether DQB1, DPB1, and DRB3/4/5 were also considered. An older report based on antigens may need updated molecular typing before a current donor decision.
Ask whether the proposed donor is a matched sibling, matched unrelated donor, mismatched unrelated donor, haploidentical relative, or cord blood unit. The acceptable degree of HLA difference and the way cell dose is weighed differ among these graft sources. A cord blood match score should not be compared directly with an adult donor score.
The planned graft-versus-host disease prophylaxis is equally important. Post-transplant cyclophosphamide, calcineurin-inhibitor approaches, antithymocyte globulin, T-cell depletion, and other strategies change the consequences of mismatch. Current guidance allows more flexibility in some platforms than older transplant literature suggests.
For every candidate donor, ask whether the recipient has current or historical donor-specific antibody. An allele match can look favorable while an untyped secondary locus creates an antibody target. Conversely, a mismatch that is not targeted by antibody may be acceptable when the transplant team has an appropriate prevention plan.
HLA-DR in kidney and other solid organs
Kidney allocation systems often consider HLA matching, but the priority assigned to DR varies by country and program. Better matching can reduce alloimmune burden and may improve long-term outcomes, yet waiting for a rare match has costs. Time on dialysis, age, comorbid disease, sensitization, and access to a living donor affect the overall decision.
In liver, heart, lung, pancreas, and intestinal transplantation, the weight of HLA-DR differs because organ urgency, ischemia, organ size, and immunobiology differ. A person should not assume that a mismatch judged acceptable for a liver would be acceptable for a kidney or stem cell graft.
After solid-organ transplant, new antibodies commonly target class II HLA, particularly DQ and DR. A mismatch count alone does not measure this risk. Medication adherence, immunosuppression exposure, inflammation, molecular mismatch, and previous immune history contribute. Programs may monitor donor-specific antibodies and graft function, but schedules differ.
Why ancestry affects donor searches
HLA alleles are inherited in haplotypes, and haplotype frequencies differ among populations. A patient is more likely to match a donor with similar ancestral genetic background, but self-identified race or ethnicity is an imperfect proxy for HLA. Mixed ancestry can create uncommon combinations that are difficult to predict from registry screening.
Registry representation affects the probability of finding an unrelated match. Underrepresented populations may have fewer available donors and greater haplotype diversity. Early typing and an early simultaneous search for related, unrelated, haploidentical, and cord options can prevent avoidable delay.
A low predicted chance of an 8/8 donor is not a reason to abandon transplantation. Modern alternative-donor approaches can provide a suitable graft for most patients. The search strategy should focus on reaching a safe transplant at the right time rather than treating a perfect match as the only successful outcome.
Patients can request a written donor-selection summary that records the chosen graft source, core HLA score, important secondary mismatches, donor-specific antibodies, and the reason one donor was preferred. This is useful when care involves more than one center and prevents a match score from being separated from the clinical reasoning behind it.
HLA results are stable, but databases and donor availability change. A search may be updated as new volunteers join, typing is refined, or a potential donor becomes unavailable. The transplant team—not the patient’s raw report—should manage these updates.
A result obtained for transplantation can remain useful for future transplants, but confirmatory sampling may still be required for identity, updated resolution, and current laboratory standards. Antibody testing must be repeated because sensitization can change even though inherited HLA does not.
References
- Donor selection guidelines: A 2025 update 2025 (Guideline)
- Histocompatibility 2024 (Review)
- Immunocompatibility in transplantation: adapting to a changing landscape 2025 (Review)
- Molecular matching tools for allocation and immunological risk stratification in transplantation 2024 (Review)
- HLA-DR/DQ eplet mismatch predicts de novo donor-specific antibody development and graft outcomes in kidney transplantation 2024
- Donor and cord blood unit selection guidelines 2025 (Guideline)
Disclaimer
This information is educational and does not determine transplant eligibility, donor selection, or an autoimmune diagnosis. HLA-DR results must be interpreted by the transplant or treating team with complete high-resolution typing, antibody testing, crossmatch data, disease status, and the planned treatment approach. Do not delay urgent transplant care or change medical treatment based on an allele report alone.
